Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour

Gut

Volumn 61, Issue 3, 2012, Pages 392-401

  Okamoto, Yasuyuki ^a,b   Sawaki, Akira ^a   Ito, Seiji ^a   Nishida, Toshirou ^c   Takahashi, Tsuyoshi ^d   Toyota, Minoru ^e   Suzuki, Hiromu ^e   Shinomura, Yasuhisa ^e   Takeuchi, Ichiro ^f   Shinjo, Keiko ^a,g   An, Byonggu ^a   Ito, Hidemi ^a   Yamao, Kenji ^a   Fujii, Makiko ^a   Murakami, Hideki ^a   Osada, Hirotaka ^a,g   Kataoka, Hiromi ^b   Joh, Takashi ^b   Sekido, Yoshitaka ^a,g   Kondo, Yutaka ^a,h  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c Police Hospital   (Japan)

^d OSAKA GENERAL MEDICAL CENTER   (Japan)

^e SAPPORO MEDICAL UNIVERSITY   (Japan)

^f NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CDH1 GENE; CONTROLLED STUDY; CPG ISLAND; DISEASE MARKER; DNA METHYLATION; DNA MICROARRAY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MGMT GENE; P16 GENE; PAX3 GENE; PRIORITY JOURNAL; RASSF1A GENE; REC8 GENE;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENES, P16; GENES, TUMOR SUPPRESSOR; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PAIRED BOX TRANSCRIPTION FACTORS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84857046177     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2011.241034     Document Type: Article

References (46)

1. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST)eupdate of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5(Suppl 2):S1-29; quiz S30.
2. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, doubleblind, placebo-controlled trial. Lancet 2009;373:1097-104.
3. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65. (Pubitemid 34747864)
4. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68. (Pubitemid 40023952)
5. Nakahara M, Isozaki K, Hirota S, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998;115:1090-5. (Pubitemid 28485599)
6. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10. (Pubitemid 36159485)
7. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch 2010;456:111-27.
8. Chen Y, Tzeng CC, Liou CP, et al. Biological significance of chromosomal imbalance aberrations in gastrointestinal stromal tumors. J Biomed Sci 2004;11:65-71. (Pubitemid 38142354)
9. Schneider-Stock R, Boltze C, Lasota J, et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 2003;21:1688-97. (Pubitemid 46638579)
10. Nemoto Y, Mikami T, Hana K, et al. Correlation of enhanced cell turnover with prognosis of gastrointestinal stromal tumors of the stomach: relevance of cellularity and p27kip1. Pathol Int 2006;56:724-31. (Pubitemid 44691158)
11. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28. (Pubitemid 34587077)
12. Toyota M, Suzuki H, Yamashita T, et al. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci 2009;100:787-91.
13. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66. (Pubitemid 37328861)
14. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005;5:223-31. (Pubitemid 40314953)
15. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet 2010;11:191-203.
16. Shen L, Kondo Y, Guo Y, et al. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet 2007;3:2023-36.
17. Omura N, Li CP, Li A, et al. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther 2008;7:1146-56.
18. Goto Y, Shinjo K, Kondo Y, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 2009;69:9073-82.
19. Torihashi S, Horisawa M, Watanabe Y. c-Kit immunoreactive interstitial cells in the human gastrointestinal tract. J Auton Nerv Syst 1999;75:38-50. (Pubitemid 29034710)
20. Colella S, Shen L, Baggerly KA, et al. Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 2003;35:146-50. (Pubitemid 36828724)
21. Gao W, Kondo Y, Shen L, et al. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis 2008;29:1901-10.
22. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9. (Pubitemid 46621810)
23. Kondo Y, Shen L, Suzuki S, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007;37:974-83. (Pubitemid 47399927)
24. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-8. (Pubitemid 41487800)
25. Yang AS, Estecio MR, Doshi K, et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004;32:e38.
26. Igarashi S, Suzuki H, Niinuma T, et al. A novel correlation between LINE-1 hypomethylation and the malignancy of gastrointestinal stromal tumors. Clin Cancer Res 2010;16:5114-23.
27. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681-6. (Pubitemid 29354851)
28. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510-22.
29. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006;55:1000-6. (Pubitemid 43962613)
30. Henze B. A multivariate two-sample test based on the number of nearest neighbor type coincidences. Ann Statist 1988;16:772-83.
31. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004;10:3291-300. (Pubitemid 38685433)
32. Ricci R, Arena V, Castri F, et al. Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol 2004;122:35-43. (Pubitemid 38849870)
33. Schneider-Stock R, Boltze C, Lasota J, et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005;11:638-45. (Pubitemid 40116890)
34. House MG, Guo M, Efron DT, et al. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg 2003;7:1004-14; discussion 14.
35. Saito K, Sakurai S, Sano T, et al. Aberrant methylation status of known methylationsensitive CpG islands in gastrointestinal stromal tumors without any correlation to the state of c-kit and PDGFRA gene mutations and their malignancy. Cancer Sci 2008;99:253-9. (Pubitemid 351228477)
36. Corless CL. Assessing the prognosis of gastrointestinal stromal tumors: a growing role for molecular testing. Am J Clin Pathol 2004;122:11-13. (Pubitemid 38849866)
37. Burri M, Tromvoukis Y, Bopp D, et al. Conservation of the paired domain in metazoans and its structure in three isolated human genes. EMBO J 1989;8:1183-90. (Pubitemid 19273287)
38. Xu H, Beasley MD, Warren WD, et al. Absence of mouse REC8 cohesin promotes synapsis of sister chromatids in meiosis. Dev Cell 2005;8:949-61. (Pubitemid 40754065)
39. Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 2006;38:149-53. (Pubitemid 43177227)
40. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10:295-304.
41. Guenther MG, Levine SS, Boyer LA, et al. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007;130:77-88. (Pubitemid 47031323)
42. Takeshima H, Yamashita S, Shimazu T, et al. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res 2009;19:1974-82.
43. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33(Suppl):245-54. (Pubitemid 36278835)
44. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A 2008;105:252-7.
45. Terada K, Okochi-Takada E, Akashi-Tanaka S, et al. Association between frequent CpG island methylation and HER2 amplification in human breast cancers. Carcinogenesis 2009;30:466-71.
46. Pellise M, Castells A, Gines A, et al. Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonographydguided fine-needle aspiration biopsy. Clin Cancer Res 2004;10:4444-9. (Pubitemid 38878887)